Abstract
AbstractThe World Health Organization published the preferred product characteristics for a Group A Streptococcus (Strep A) vaccine in 2018. Based on these parameters for the age of vaccination, vaccine efficacy, duration of protection from vaccine-derived immunity, and vaccination coverage, we developed a static cohort model to estimate the projected health impact of Strep A vaccination at the global, regional, and national levels and by country-income category. We used the model to analyse six strategic scenarios. Based on Strep A vaccine introduction between 2022 and 2034 for the primary scenario, we estimated vaccination at birth for 30 vaccinated cohorts could avert 2.5 billion episodes of pharyngitis, 345 million episodes of impetigo, 1.3 million episodes of invasive disease, 24 million episodes of cellulitis, and 6 million cases of rheumatic heart disease globally. Vaccination impact in terms of burden averted per fully vaccinated individual is highest in North America for cellulitis and in Sub-Saharan Africa for rheumatic heart disease.
Publisher
Cold Spring Harbor Laboratory
Reference23 articles.
1. The global burden of group A streptococcal diseases
2. Global, Regional, and National Burden of Rheumatic Heart Disease, 1990–2015
3. Group A Streptococcal Diseases and Their Global Burden;Microbiol Immunol,2012
4. Sims Sanyahumbi, A. , Colquhoun, S. , Wyber, R. & Carapetis, J. R. Global disease burden of group A streptococcus. in Streptococcus pyogenes : Basic Biology to Clinical Manifestations (eds. Ferretti, J. J. , Stevens, D. L. & Fischetti, V. A. ) (University of Oklahoma Health Sciences Center, 2016).
5. Stroke and rheumatic heart disease: A systematic review of observational studies
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献